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Thus the same transmitter may evoke fast excitation, slow excita-
tion, slow inhibition, plus other cellular responses, often within the 
same group of CNS neurons. These actions underlie most, if not 
all major CNS functions, and GluR are the therapeutic targets of 
choice in a wide range of psychiatric and neurological diseases. As 
such there is great emphasis on CNS GluR in both academic and 
industrial research programs.
Our emphasis is on GluR in the peripheral nervous system 
(PNS). Because of the blood brain barrier, and the possibility 
to design drugs that may or may not cross it, GluR in the PNS 
clearly represent a range of targets distinct from CNS GluR. There 
is good evidence for involvement of GluR in the enteric nervous 
system (Liu and Kirchgessner, 2000; Foong and Bornstein, 2009), 
but our emphasis here is on GluR on sensory neurons that project 
to the CNS, which are well known to release glutamate from their 
central terminals (Millan, 1999; Bonham and Chen, 2002). These 
terminals are well established as targets for synaptic modulation 
by GluR, both in the spinal cord and brain stem. Therefore sensory 
neurons synthesize and release glutamate, and express GluR. We 
have demonstrated the existence of all iGluR and mGluR in the 
vagal sensory (nodose) ganglia, including neurons projecting to the 
stomach, with investigations in five species. If all 21 subtypes of 
these receptors were expressed on individual afferents innervating 
the gastrointestinal tract it would represent a complex regulatory 
system, with the possibility of parallel lines of peripheral control of 
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Glutamate (Glu) is the major excitatory neurotransmitter in the 
central nervous system (CNS). It also acts to modulate synaptic 
transmission both pre- and post-synaptically. These actions are 
mediated via a large range of ionotropic (iGluR, NMDA, AMPA, 
and kainate), and metabotropic (mGluR, group I, II, III) receptors. 
iGluR are directly coupled to cation channels, and their activation 
evokes fast synaptic events which may lead to longer-term changes 
in excitability (Bleakman and Lodge, 1998; Yamakura and Shimoji, 
1999). mGluR exist as eight subtypes of G-protein coupled recep-
tor: Group I (mGluR1 and 5) are excitatory and are believed to act 
mainly via Gαq/phospholipase C. Group II (mGluR2 and 3), and 
III (mGluR4, 6, 7, and 8) inhibit adenylate cyclase and alter cation 
currents via Gαi and Gβγ subunits respectively (Conn and Pin, 
1997; Schoepp et al., 1999; Figure 1).
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Metabotropic glutamate receptors (mGluR) have a diverse range of structures and molecular 
coupling mechanisms. There are eight mGluR subtypes divided into three major groups. Group I 
(mGluR1 and 5) is excitatory; groups II (mGluR2 and 3) and III (mGluR 4, 6, and 7) are inhibitory. 
All mGluR are found in the mammalian nervous system but some are absent from sensory 
neurons. The focus here is on mGluR in sensory pathways from the viscera, where they have 
been explored as therapeutic targets. Group I mGluR are activated by endogenous glutamate or 
constitutively active without agonist. Constitutive activity can be exploited by inverse agonists 
to reduce neuronal excitability without synaptic input. This is promising for reducing activation 
of nociceptive afferents and pain using mGluR5 negative allosteric modulators. Many inhibitory 
mGluR are also expressed in visceral afferents, many of which markedly reduce excitability. Their 
role in visceral pain remains to be determined, but they have shown promise in inhibition of the 
triggering of gastro-esophageal reflux, via an action on mechanosensory gastric afferents. The 
extent of reflux inhibition is limited, however, and may not reach a clinically useful level. On the 
other hand, negative modulation of mGluR5 has very potent actions on reflux inhibition, which 
has produced the most likely candidates so far as therapeutic drugs. These act probably outside 
the central nervous system, and may therefore provide a generous therapeutic window. There 
are many unanswered questions about mGluR along visceral afferent pathways, the answers 
to which may reveal many more therapeutic candidates.
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occlude one another. We do not yet know if there is expression of 
multiple GluR on individual afferents innervating the gastrointes-
tinal tract and how their expression differs from the innervation of 
other tissues. What is often overlooked is that release of glutamate 
and expression of GluR is not confined to central terminals of 
sensory neurons.
mGlur effects on vaGal afferent pathways
perIpheral
Expression of all eight mGluRs has been demonstrated in vagal 
afferent cell bodies of the nodose ganglia in several species 
(Hoang and Hay, 2001; Page et al., 2005), although we could not 
detect expression of mGluR3 and six mRNA in human and fer-
ret nodose ganglia (Page et al., 2005). Immunohistochemistry, 
however revealed expression of all eight in ferret nodose ganglia. 
Functionally, vagal afferents from the upper gastrointestinal tract 
may be classified into three types, according to their mechanical 
sensitivity. Tension receptors respond only to distension and con-
traction of smooth or striated muscle; mucosal receptors respond 
only to mucosal stroking, and tension-mucosal receptors respond 
to both stimuli but are found so far only in ferret esophagus. 
Studies in mouse and ferret indicate that group II and III receptor 
agonists inhibit mechanical sensitivity of vagal gastro-esophageal 
afferents, whereas a group I agonist had no effect (Page et al., 
2005). Ferret afferents were more effectively inhibited than mouse 
afferents, which may reflect greater expression and/or coupling of 
receptors; alternatively it may reflect the greater dynamic range of 
the afferents allowing inhibition to be more easily seen. A non-
selective group III antagonist given alone increased mechanosensi-
tivity of ferret afferents, indicating a role for endogenous glutamate 
causing ongoing activation via one or more classes of group III 
receptors on vagal afferents. We have since found more specific, 
as yet unpublished, evidence for a role of group III receptors in 
ongoing modulation. In the mGluR4 receptor knockout mouse, 
the sensitivity of mucosal receptors was increased in comparison to 
wild types. However, tension receptors were similar in knockouts 
and wild types, suggesting that mGluR4 may have a specific role. 
Neither of these classes of afferents was altered upon deletion of 
the mGluR8 gene (Figure 2).
Since the greatest effects of group III activation were seen in 
ferret afferents, it is perhaps not surprising that deleting one of 
these receptors at a time in mouse has unremarkable effects. No 
further studies of group III mGluR in mice were pursued. It may 
be important for group III mGluR to operate as heterodimers, as 
is seen with many other GPCR (Marshall, 2001), but evidence is 
lacking for direct associations between different group III mGluR. 
That they are co-expressed is highly likely, since our cell counts indi-
cate there is considerable overlap of expression of different mGluR 
immunoreactivity within nodose neurons innervating the stomach, 
because most of them showed expression in 80–90% of cell bodies.
Metabotropic glutamate receptor 5 antagonists significantly 
reduce mechanosensitivity of gastro-esophageal vagal afferents in 
ferret and mouse (Slattery et al., 2006; Young et al., 2007), but not in 
guinea pig (Zagorodnyuk et al., 2003), indicating opposing excita-
tory and inhibitory roles for endogenous glutamate, and differences 
between species. The fact that a group I agonist was ineffective, 
yet an antagonist may cause inhibition, suggests that receptors are 
fully active under resting conditions. This may be due to gluta-
mate released locally, or to constitutive activity, which is a notable 
feature of group I mGluR (Ango et al., 2001). The locally available 
glutamate would probably be released from the afferent endings 
themselves. In the case of tension receptors, these endings take the 
form of intraganglionic laminar endings (IGLE) in the stomach and 
esophagus (Zagorodnyuk and Brookes, 2000; Zagorodnyuk et al., 
2001); IGLEs express the vesicular glutamate transporters VGLUT1 
and VGLUT2 (Raab and Neuhuber, 2003, 2004; Ewald et al., 2006) 
Figure 1 | Classification of glutamate receptors.
Figure 2 | responses of gastro-esophageal vagal afferents to 
mechanical stimulation in mice deficient in mglur4 (A*) or mglur8 (B). 
(i) The effects of disrupting mGluR on the responses to circumferential tension 
(average impulses s−1 over stimulus duration of 1 min) of tension receptors. 
(ii) The effects of disrupting mGluR on the responses to mucosal stroking 
(impulses per stroke, mean of eight strokes) of mucosal receptors. The graphs 
show the mean ± SEM. Significant differences between mGluR+/+ (•) and 
−/− (°) mice (assessed using two-way ANOVA) is indicated adjacent to the 
response curves (*p < 0.05). n = number of afferents recorded. *Previously 
presented. The metabotropic glutamate receptor mGluR4 is required for 
normal visceral mechanotransduction (Page et al., 2004).
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II and III mGluR, but not by Group I mGluR (Glaum and Miller, 
1993; Liu et al., 1998; Chen et al., 2002). Therefore, despite evidence 
of mGluR5 expression in the vagus in ferrets (Page et al., 2005) 
central mGluR5 seems unlikely to have a major functional role in 
vagal afferent terminals.
Labeling for mGluR4 and mGluR8 is abundant in gastric vagal 
afferents in the ferret nodose ganglion, at their termination site in 
the NTS (subnucleus gelatinosus) and in gastric vagal motorneu-
rons, while labeling for mGluR6 and mGluR7 is weaker in these 
regions (Page et al., 2005; Young et al., 2008a). The mGluR8 agonist 
DCPG (i.c.v.) inhibited or markedly attenuated responses of most 
NTS neurons excited by gastric distension. The effects of DCPG 
were significantly reversed by the group III mGluR antagonist 
MAP4. In contrast, none of the NTS neurons inhibited by gastric 
distension were affected by DCPG. This indicates that group III 
mGluR are expressed in both peripheral and central vagal pathways, 
and that mGluR8 within the NTS selectively reduces excitatory 
transmission along gastric vagal pathways.
mGlur effects on spInal afferent pathways
Group I mGluR antagonists, particularly antagonists for mGluR5, 
have received a great deal of interest in their potential as analgesics 
for somatic pain and anxiolytics (Swanson et al., 2005). mGluR5 
is expressed in various regions along the somatosensory pathway, 
including the dorsal horn of the spinal cord (laminae I and II) and 
pain-related CNS centers (Valerio et al., 1997; Neto et al., 2000; 
Tao et al., 2000). Selective mGluR5 antagonists, such as MPEP and 
MTEP, have been developed and these compounds have shown 
analgesic properties in several animal models of inflammatory 
and neuropathic somatic pain (Gasparini et al., 1999; Karim et al., 
2001; Walker et al., 2001a,b; Fisher et al., 2002; Hudson et al., 2002; 
Cosford et al., 2003; Zhu et al., 2004; Varty et al., 2005).
perIpheral
As in the nodose ganglia, there is evidence for expression of all mGluR 
in the dorsal root ganglia (DRG; Carlton and Hargett, 2007). Specific 
data on expression within DRG neurons innervating the gut are lack-
ing, but functional evidence exists for some mGluR. It is unwise to 
extrapolate from observations in whole DRG to what is likely to be 
the case for visceral afferents. They make up a small proportion of 
DRG neurons – as little as 2% of the total. The majority of visceral 
DRG afferents are small-medium diameter peptidergic neurons (Tan 
et al., 2009), but even as such they may differ markedly from other 
phenotypically similar neurons (Brierley et al., 2008). Therefore 
there is much work yet to be done to determine the selectivity of 
expression of mGluR on visceral spinal afferents. There are several 
subtypes of visceral spinal afferents, which preferentially travel via 
the splanchnic (thoracolumbar) or pelvic (lumbosacral) innerva-
tion. The splanchnic nerves provide innervation of the abdominal 
viscera, whereas the pelvic nerve is restricted to pelvic organs, with 
overlap in the distal colon. Low threshold mucosal, muscular, and 
muscular-mucosal afferents are almost exclusive to the pelvic inner-
vation and to the distal colon and rectum. High threshold serosal 
afferents are found in both pathways, and high threshold mesenteric 
afferents are carried exclusively in the splanchnic nerves. Mucosal, 
muscular, and muscular-mucosal receptors behave in a similar way 
and possess peripheral synaptic specializations (Neuhuber, 1987). 
These facts point strongly to an effector role for IGLEs in periph-
eral glutamatergic transmission. In view of evidence of mGluR5 
expression in ferret gastric vagal afferents, peripheral transport of 
this receptor and inhibition of tension and TM receptor responses 
by 2-methyl-6-(phenylethynyl)-pyridine (MPEP), these findings 
support the notion that mechanical stimulation leads to endog-
enous glutamate release from gastro-esophageal IGLEs which in 
turn activates autoreceptors on tension and TM receptors, an effect 
that may be blocked by mGluR antagonists. Results from studies of 
gastro-esophageal vagal afferents in ferret in vivo confirmed earlier 
in vitro findings that an mGluR5 antagonist reduces mechanosen-
sitivity of ferret tension receptors (Young et al., 2007). mGluR5 
antagonism did not inhibit mucosal receptor mechanosensitivity 
in ferret, which may result if either mGluR5 were absent from 
this class of afferents in ferrets, or if mucosal receptors possessed 
mGluR5 that were inaccessible to endogenous glutamate released 
from IGLEs. In mouse mucosal afferents, however, an mGluR5 
antagonist caused potent inhibition of mucosal afferents (Slattery 
et al., 2006), which could be attributable either to increased diffu-
sion of glutamate through the mouse gut, or differences in receptor 
expression. Studies on mGluR1 on vagal afferents, which shares 
many features with mGluR5, are lacking, which represents a sig-
nificant gap in the literature.
central
Electrophysiological studies demonstrated that single neu-
rons excited or inhibited by gastric distension can be identi-
fied throughout the ferret NTS (Young  et al., 2007, 2008a). 
Intracerebroventricular MPEP acted rapidly and potently to inhibit 
a minority of NTS neurons that showed excitatory responses to 
gastric distension, however the majority of neurons tested with 
MPEP were only modestly attenuated or showed no effect. All 
neurons inhibited by gastric distension were unaffected by MPEP. 
These findings suggest that mGluR5 are functionally expressed 
only on excitatory pathways through the NTS and expression is 
restricted to a small subset of these. This finding contrasts with 
our earlier results with the GABA(B) receptor agonist baclofen, 
which reversibly inhibited all NTS neurons excited or inhibited 
by gastric distension (Partosoedarso et al., 2001). Our data on 
retrograde tracing of central terminals of gastric vagal afferents 
in ferrets showed that, like the rat (Shapiro and Miselis, 1985) 
and cat (Gwyn et al., 1979), ferret gastric vagal afferents terminate 
preferentially in the subnucleus gelatinosus in rostral regions of 
dorsal vagal complex with terminal fields extending into the dorsal 
mnNTS and fibers extending dorsomedially from the solitary tract 
(Young et al., 2007, 2008b). Combined with dual label immuno-
histochemistry these anatomical findings support a minor role 
for mGluR5 on a subset of second- or higher-order excitatory 
interneurons linked to gastric mechanoreceptor input. This was 
apparent due to (i) a lack of significant co-localization between 
mGluR5 immunoreactivity and retrogradely traced gastric vagal 
afferent terminal fields in the NTS, combined with (ii) high level 
mGluR5 expression in lateral regions of the mnNTS and solitary 
tract, and (iii) the absence of mGluR5 on DMV perikarya (Young 
et al., 2007). Additional support for this view is provided by the 
limited functional effect of central MPEP plus proof of presynaptic 
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Metabotropic glutamate receptor 5 antagonists appear to modulate 
somatic nociceptive processing at various levels of the nervous system 
in addition to peripheral afferent endings, including spinal dorsal 
horn and supraspinal sites (Dogrul et al., 2000; Neugebauer, 2002; 
Zhu et al., 2005), indicating that mGluR5 is involved in mediating 
or positively modulating pain. Central analgesic effects of mGluR5 
antagonists have been extensively reported in different models, how-
ever contribution of mGluR5 in specific central regions has not been 
assessed in visceral pain. Since after peripheral administration the 
brain penetration of MPEP and MTEP is relatively high (Anderson et 
al., 2003) central sites of action mediating the analgesic effects on vis-
ceral pain in addition to peripheral sites are quite likely in our recent 
study (Lindstrom et al., 2008). Hu et al. (2009) recently demonstrated 
that ERK-mediated phosphorylation of Kv4.2 occurs downstream of 
mGluR5 activation in spinal cord dorsal horn neurons. Activation 
of group I mGluRs inhibited Kv4.2-mediated A-type K+ currents 
and increased neuronal excitability in dorsal horn neurons. These 
effects were mediated by activation of mGluR5, but not mGluR1.
There is good evidence that group II and group III mGluR at 
a supraspinal site may become induced in somatic inflammatory 
pain, but that they may be a poor clinical target for pain due to 
tolerance development and effects on other systems (Jones et al., 
2005; Marabese et al., 2007). In this context, inhibitory mGluR 
may be recruited as an adaptive response to pain in a similar way 
to opiodergic pain control.
mGlur as clInIcal tarGets
Gastro-esophaGeal reflux dIsease
One of our major findings with regard to a clinical indication for 
mGluR was that antagonism of mGluR5 potently inhibits the trig-
gering of transient LES relaxations by a gastric load, and thereby 
reduces the number of reflux episodes. This suggests that mGluR5 
antagonists may be novel and efficacious strategies in the man-
agement of gastro-esophageal reflux disease. This suggests that 
endogenous activation of mGluR5 is an important component of 
the pathway(s) triggering or regulating transient lower esophageal 
sphincter relaxation (TLESR). The close correlation between inhibi-
tion of reflux events and inhibition of TLESR by mGluR5 antago-
nists reconfirms that TLESR is the major mechanism of reflux in 
ferrets as it is in other species (Blackshaw et al., 1998; Frisby et al., 
2005). Our ferret data are corroborated by studies in dogs which 
also show a potent and significant inhibitory effect of MPEP on 
TLESR (Jensen et al., 2005). We found on the other hand that an 
agonist of excitatory group I mGluR had the opposite effect to the 
antagonists by tending to stimulating TLESR, as would be expected, 
although the effects of agonists were inconsistent and not statistically 
significant. In contrast to effects of group I agonism, stimulation of 
the inhibitory group III mGluR reduced the triggering of TLESR. 
Group III agonists were, however, considerably less potent than 
group I (mGluR5) antagonists. A recent clinical trial indicated that 
the mGluR5 negative allosteric modulator ADX10059 reduced acid 
reflux which was associated with improvement in clinical symptoms 
in patients with reflux disease. ADX10059 therefore appears to have a 
potential role in the clinical management of reflux disease (Keywood 
et al., 2009). The proposed mechanism of action of mGluR on trig-
gering of TLESR is shown schematically in Figure 3.
to their vagal counterparts (mucosal,  tension, and tension-mucosal). 
In those subtypes that are distension-sensitive, responses to disten-
sion are more likely to reach maximum at noxious levels than in 
vagal afferents, and some of these have been termed wide dynamic 
range afferents (Rong et al., 2004). Serosal and mesenteric afferents 
respond only at noxious levels of distension. (Brierley et al., 2008, 
2009; Hughes et al., 2009).
Our preliminary data indicate no effect of group II or group 
III agonists on rat colonic afferents in an isolated preparation 
(Phillis and Blackshaw, unpublished). However, recent data indicate 
that group II mGluRs and TRPV1 receptors are co-expressed on 
peripheral nociceptors and activation of mGluRs can inhibit pain-
ful somatosensory transmission following TRPV1 activation. The 
data are consistent with group II and TRPV1 receptors being linked 
intracellularly by the cAMP/PKA pathway (Carlton et al., 2009).
Writhing behavior and c-fos expression in the spinal cord evoked 
by acetic acid are inhibited by MPEP (Bianchi et al., 2003; Zhu et 
al., 2004). However, administration of acetic acid into the perito-
neal cavity is not regarded as a selective visceral stimulus since the 
peritoneum, a partly somatic structure, and probably other somatic 
structures, are involved in the responses observed (Martinez et al., 
1999; Laird et al., 2001). We found that mGluR5 receptor antagonists 
inhibit the visceromotor (VMR) and autonomic responses to color-
ectal distension (CRD) in conscious rats. An action at peripheral sites 
mediating the analgesic effects was considered a possibility. This was 
tested by recording from two major populations of colonic mech-
anoreceptors – pelvic muscular and muscular/mucosal afferents, and 
splanchnic serosal afferents (Lindstrom et al., 2008). These studies 
demonstrated that MTEP was able to inhibit mechanosensitivity in 
both populations of afferents, corresponding to those responding 
at low and high threshold to distension in situ. This provides the 
first evidence for a peripheral site of action of mGluR5 antagonists 
contributing to the inhibition of the responses to CRD. It does not, 
however, rule out an additional action in the central nervous sys-
tem, at either spinal or supraspinal sites. A study of mGluR5 in the 
bladder sensory pathway reached the opposite conclusion – that 
no effect of an antagonist could be seen on afferents in the isolated 
preparation, but inhibition of behavioral and reflex responses was 
readily observed in vivo (Hu et al., 2009). Therefore there may be 
different roles of mGluR5 in different visceral sensory pathways.
Inhibitory effects of MPEP on the VMR and the cardiovascular 
response to CRD indicate an involvement of mGluR5 in visceral 
sensory mechanisms, as previously suggested for somatic pain 
(Gasparini et al., 1999; Karim et al., 2001; Walker et al., 2001a,b; 
Fisher et al., 2002; Hudson et al., 2002; Cosford et al., 2003; Zhu et 
al., 2004; Varty et al., 2005). A peripheral site of action is perhaps 
not surprising since mGluR5 is strongly expressed in small diam-
eter dorsal root ganglion neurons (Valerio et al., 1997; Walker et al., 
2001b) and peripheral axons (Bhave et al., 2001; Walker et al., 2001b), 
although these studies did not discriminate between ganglion neu-
rons innervating the colon and others. Nevertheless, several reports 
showed also a significant analgesic activity of peripheral mGluR5 
in models of somatic pain (Bhave et al., 2001; Walker et al., 2001b).
Zhou et al. (2001) found that mGluR1 are present on peripheral 
cutaneous axons and their activation contributes to mechanical 
allodynia and inflammatory pain but not thermal hyperalgesia. No 
studies of this type are evident as yet on visceral afferents.
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throughout this circuit, both peripherally and centrally. Their role appears to be 
mainly presynaptic, and in some cases mainly peripheral (see text). Their role within 
the program generator and along vagal motor pathways is not known.
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